Literature DB >> 14970494

Antibody humanization by CDR grafting.

Benny K C Lo1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14970494     DOI： 10.1385/1-59259-666-5:135

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


× No keyword cloud information.
  11 in total

1.  Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.

Authors:  Andreas Lehmann; Josephine H F Wixted; Maxim V Shapovalov; Heinrich Roder; Roland L Dunbrack; Matthew K Robinson
Journal:  MAbs       Date:  2015-09-04       Impact factor: 5.857

2.  Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.

Authors:  Kannika Khantasup; Warangkana Chantima; Chak Sangma; Kanokwan Poomputsa; Tararaj Dharakul
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-12

3.  Evolution of highly active enzymes by homology-independent recombination.

Authors:  Karl E Griswold; Yasuaki Kawarasaki; Nada Ghoneim; Stephen J Benkovic; Brent L Iverson; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-11       Impact factor: 11.205

4.  Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.

Authors:  Kevin O Saunders; Lingshu Wang; M Gordon Joyce; Zhi-Yong Yang; Alejandro B Balazs; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Rebecca S Rudicell; Ivelin S Georgiev; Lijie Duan; Kathryn E Foulds; Mitzi Donaldson; Ling Xu; Stephen D Schmidt; John-Paul Todd; David Baltimore; Mario Roederer; Ashley T Haase; Peter D Kwong; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2015-08       Impact factor: 5.103

5.  Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection.

Authors:  Kevin O Saunders; Amarendra Pegu; Ivelin S Georgiev; Ming Zeng; M Gordon Joyce; Zhi-Yong Yang; Sung-Youl Ko; Xuejun Chen; Stephen D Schmidt; Ashley T Haase; John-Paul Todd; Saran Bao; Peter D Kwong; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

6.  Characterization of a lipopolysaccharide-targeted monoclonal antibody and its variable fragments as candidates for prophylaxis against the obligate intracellular bacterial pathogen Coxiella burnetii.

Authors:  Ying Peng; Laura Schoenlaub; Alexandra Elliott; William J Mitchell; Guoquan Zhang
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

7.  Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.

Authors:  Ivelin S Georgiev; Rebecca S Rudicell; Kevin O Saunders; Wei Shi; Tatsiana Kirys; Krisha McKee; Sijy O'Dell; Gwo-Yu Chuang; Zhi-Yong Yang; Gilad Ofek; Mark Connors; John R Mascola; Gary J Nabel; Peter D Kwong
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

8.  Optimization algorithms for functional deimmunization of therapeutic proteins.

Authors:  Andrew S Parker; Wei Zheng; Karl E Griswold; Chris Bailey-Kellogg
Journal:  BMC Bioinformatics       Date:  2010-04-09       Impact factor: 3.169

9.  Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.

Authors:  Vladimir Vexler; Li Yu; Chandrasena Pamulapati; Rosario Garrido; Hans Peter Grimm; Priya Sriraman; Sandhya Bohini; Michael Schraeml; Usha Singh; Michael Brandt; Stefan Ries; Han Ma; Klaus Klumpp; Changhua Ji
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

10.  Small-angle x-ray scattering screening complements conventional biophysical analysis: comparative structural and biophysical analysis of monoclonal antibodies IgG1, IgG2, and IgG4.

Authors:  Xinsheng Tian; Annette E Langkilde; Matthias Thorolfsson; Hanne B Rasmussen; Bente Vestergaard
Journal:  J Pharm Sci       Date:  2014-04-02       Impact factor: 3.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.